Your browser doesn't support javascript.
loading
May Measurement Month 2021: an analysis of blood pressure screening results from Australia.
Carnagarin, Revathy; Leigh, James; Tan, Isabella; Gnanenthiran, Sonali; Yang, Jun; Beaney, Thomas; Clarke, Jonathan; Poulter, Neil R; Brockman, Derrin; Schlaich, Markus P.
Afiliação
  • Carnagarin R; Dobney Hypertension Centre, Medical School-Royal Perth Hospital Unit/Royal Perth Hospital Research Foundation, University of Western Australia, Level 3, MRF Building, Rear 50 Murray St, Perth, WA 6000, Australia.
  • Leigh J; Geraldton Regional Hospital, Western Australian Country Health Service Midwest, Geraldton, Australia.
  • Tan I; School of Public Health, Centre of Clinical Research and Education, Curtin University, Bentley, WA 6102, Australia.
  • Gnanenthiran S; Department of Biomedical Sciences, Faculty of Medicine, Macquarie University, Sydney, NSW 2109, Australia.
  • Yang J; The George Institute for Global Health, Sydney, NSW, Australia.
  • Beaney T; Department of Medicine, Monash University, Clayton VIC 3168, Australia.
  • Clarke J; Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
  • Poulter NR; Department of Primary Care and Public Health, Imperial College London, St Dunstan's Road, London W6 8RP, UK.
  • Brockman D; Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
  • Schlaich MP; Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
Eur Heart J Suppl ; 26(Suppl 3): iii14-iii16, 2024 Jun.
Article em En | MEDLINE | ID: mdl-39055591
ABSTRACT
May Measurement Month (MMM) is a global and national blood pressure (BP) screening campaign initiated by the International Society of Hypertension to improve awareness of BP worldwide. This study reports on the findings of the MMM21 campaign in Australia. Adult participants (≥18 years) were screened through opportunistic sampling across Australia between 1 May and 30 November 2021. Trained volunteers recorded standardized BP measurements from community volunteer participants along with demographic data, lifestyle factors, comorbidities, and history of COVID-19 infection and vaccination. Hypertension was defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg and/or taking antihypertensive medication. Data were collated and analysed centrally using the current MMM protocol and presented after the imputation of missing BP readings. A total of 1307 participants were screened in 2021, comprising 652 (49.9%) females and 654 (50.0%) males with a mean age of 48 years (SD 20.1). Of all 1307 participants, 524 (40.1%) had hypertension. Of participants with hypertension, 65.4% were aware and 59.3% were on antihypertensive medication. Of 311 participants on antihypertensive medication, 54.7% had controlled BP. Of all 524 participants with hypertension, 32.5% had controlled BP. The current 2021 data may indicate some progress in creating BP awareness; however, consecutive Australian data obtained since 2017 demonstrated stagnating treatment, and control rates compared with global rates and those in other high-income countries. Concerted efforts from all stakeholders will be required to further improve BP awareness, treatment, and control rates in Australia.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article